Systemic treatment of advanced non-small cell lung cancer

Drugs of Today

Volumn 40, Issue 8, 2004, Pages 697-710

  Traynor, Anne M ^a   Schiller, Joan H ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; BORTEZOMIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOOXYGENASE 2 INHIBITOR; DOCETAXEL; ERLOTINIB; GEFITINIB; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; ISIS 3521; MITOMYCIN C; MONOCLONAL ANTIBODY; N ACETYLSARCOSYLGLYCYLVALYL DEXTRO ALLOISOLEUCYLTHREONYLNORVALYLISOLEUCYLARGINYLPROLINE ETHYLAMIDE; NAVELBINE; PACLITAXEL; SORAFENIB; TIPIFARNIB; TIRAPAZAMINE; UNCLASSIFIED DRUG; VINBLASTINE; VINDESINE;

ADVANCED CANCER; ALOPECIA; BONE MARROW SUPPRESSION; BRONCHOSPASM; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COMORBIDITY; CONSTIPATION; DIARRHEA; DYSPNEA; ELDERLY CARE; ERYTHEMA; FEBRILE NEUTROPENIA; FEVER; FLUID RETENTION; FLUSHING; HEMATOLOGIC DISEASE; HUMAN; HYPERSENSITIVITY REACTION; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOTENSION; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; META ANALYSIS; NEPHROTOXICITY; NEUROTOXICITY; OTOTOXICITY; PERIPHERAL NEUROPATHY; QUALITY OF LIFE; RASH; REVIEW; SENSORY NEUROPATHY; SIDE EFFECT; UNITED STATES;

CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; COMBINED MODALITY THERAPY; HUMANS; LUNG NEOPLASMS; MULTICENTER STUDIES; RANDOMIZED CONTROLLED TRIALS; RETROSPECTIVE STUDIES;

EID: 4644343143     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2004.40.8.850472     Document Type: Review

References (107)

1. Jemal, A., Thomas, A., Murray, T., Thun, M. Cancer statistics, 2002. CA Cancer J Clin 2002, 52: 23-47.
2. Vokes, E.E., Herndon, U.E., II, Crawford, J. et al. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: Cancer and leukemia group B study 9431. J Clin Oncol 2002, 20: 4191-8.
3. Furuse, K., Fukuoka, M., Kawahara, M. et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999, 17: 2692-9.
4. Mountain, C.F. Revisions in the international system for staging lung cancer. Chest 1997, 111: 1710-7.
5. Schiller, J., Harrington, D., Belani, C. et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 2002, 346: 92-8.
6. Socinski, M.A., Morris, D.E., Masters, G.A., Lilenbaum, R. Chemotherapeutic management of stage IV non-small cell lung cancer. Chest 2003, 123 (1 Suppl.): 226S-243S.
7. Johnson, D. Evolution of cisplatin-based chemotherapy in non-small cell lung cancer: A historical perspective and the Eastern Cooperative Oncology Group Experience. Chest 2000, 117: 133S-137S.
8. Chu, E., DeVita, V.T. Physicians' Cancer Chemotherapy Drug. Manual 2002. Jones and Bartlett Publishers, Sudbury, Massachusettes 2002.
9. Grilli, R., Oxman, A.D., Julian, J.A. Chemotherapy for advanced non-small-cell lung cancer: How much benefit is enough? J Clin Oncol 1993, 11: 1866-72.
10. Anonymous. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995, 311: 899-909.
11. Marino, P., Pampallona, S., Preatoni, A., Cantoni, A., Inveinezzi, F. Chemotherapy vs. supportive care in advanced non-small cell lung cancer: Results of a meta-analysis of the literature. Chest 1994, 106:861-5.
12. Anonymous. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group. J Natl Cancer Inst 1999, 91: 66-72.
13. Anderson, H., Hopwood, P., Stephens, R. et al. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer - A randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer. Br J Cancer 2000, 83: 447-53.
14. Ranson, M., Davidson, N., Nicolson, M. et al. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 2000, 92: 1074-80.
15. Roszkowski, K., Pluzanska, A., Krzakowski, M. et al. A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer 2000, 27: 145-57.
16. Dorr, R.T., Von Hoff, D.D. Cancer Chemotherapy Handbook. Appleton and Lange, Norwalk, Connecticut 1994.
17. Cullen, M., Billingham, J., Woodroffe, C. et al. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: Effects on survival and quality of life. J Clin Oncol 1999, 17:3188-94.
18. Montazeri, A., Gillis, C.R., McEwen, J. Quality of life in patients with lung cancer: A review of literature from 1970 to 1995. Chest 1998, 113: 467-81.
19. Wozniak, A., Crowley, J.J., Balcerzak, S.P. et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: A Southwest Oncology Group study. J Clin Oncol 1998, 16:2459-65.
20. von Pawel, J., von Roemeling, R., Gatzemeier, U. et al. Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group. Cisplatin and tirapazamine in subjects with advanced previously untreated non-small-cell lung tumors. J Clin Oncol 2000, 18: 1351-9.
21. Sandier, A., Nemunaitis, J., Denham, C. et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 2000, 18: 122-30.
22. Gatzemeier, U., von Pawel, J., Gottfried, M. et al. Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 2000, 18: 3390-9.
23. Fossella, R, Pereira, J.R., von Pawel, J. et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: The TAX 326 study group. J Clin Oncol 2003, 21: 3016-24.
24. Rosell, R., Gatzemeier, U., Betticher, D. et al. Phase III randomized trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small cell lung cancer: A cooperative multinational trial. Ann Oncol 2002, 13: 1539-49.
25. Klastersky, J., Sculier, J., Lacroix J. et al. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer, protocol 07861. J Clin Oncol 1990, 8: 1556-62.
26. Jelic, S., Mitrovic, L., Radosavljevic, D. et al. Survival advantage for carboplatin substituting cisplatin in combination with vindesine and mitomycin C for stage IIIB and IV squamous-cell bronchogenic carcinoma: A randomized phase III study. Lung Cancer 2001; 34: 1-13.
27. Zatloukal, P., Petruzelka, L., Zemanova, M. et al. Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: A phase III randomized trial. Lung Cancer 2003, 41: 321-31.
28. Gebbia, V., Galetta, D., Caruso, M. et al. Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide+gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage IIIB-IV non small cell lung carcinoma: A prospective randomized phase III trial of the Gruppo Oncologico Italia Meridionale. Lung Cancer 2003, 39: 179-89.
29. Huang, C., Langer, C., Minniti, C. et al. Phase III toxicity trial of carboplatin (Cb) plus either docetaxel (D) or paclitaxel (P) in advanced non-small cell lung cancer (NSCLC): Preliminary findings of OPN-001. Proc Am Soc Clin Oncol 2002, 21: 337a. Abstr. 1347.
30. 2) plus carboplatin (6 AUC) in advanced non-small-cell lung cancer (NSCLC): A multicenter randomized trial. Hellenic Cooperative Oncology Group (HeCOG). Ann Oncol 2000, 11: 799-805.
31. Kelly, K., Crowley, J., Bunn, P. et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: A Southwest Oncology Group trial. J Clin Oncol 2001, 19: 3210-8.
32. Ramalingam, S., Bonomi, P., Dobbs, T. et al. Docetaxel and carboplatin for advanced non-small cell lung cancer (NSCLC): Dose of carboplatin influences outcome. Proc Am Soc Clin Oncol 2002, 21: 316a. Abstr. 1263.
33. Scagliotti, G., De Marinis, R, Rinaldi, M. et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002, 20: 4285-91.
34. Weick, J., Crowley, J., Natale, R. et al. A randomized trial of five cisplatin-containing treatments in patients with metastatic non-small cell lung cancer: A Southwest Oncology Group Study. J Clin Oncol 1991, 9: 1157-62.
35. Ruckdeschel, J., Finkelstein, D., Ettinger, D. et al. A randomized trial of the four most active regimens for metastatic non-small cell lung cancer. J Clin Oncol 1986, 4: 14-22.
36. Sculier, J., Lafitte, J., Lecomte, J. et al. A three-arm phase III randomised trial comparing combinations of platinum derivatives, ifosfamide and/or gemcitabine in stage IV non-small-cell lung cancer. Ann Oncol 2002, 13: 874-82.
37. Souquet, P., Tan, E., Rodrigues Pereira, J. et al. GLOB-1: A prospective randomised clinical phase III trial comparing vinorelbine-cisplatin with vinorelbine-ifosfamide-cisplatin in metastatic non-small-cell lung cancer patients. Ann Oncol 2002, 13: 1853-61.
38. Rudd, R., Gower, N., James, L. Phase III randomised comparison of gemcitabine and carboplatin (GC) with mitomycin, ifosfamide and cisplatin (MIP) in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2002, 21: 293a. Abstr. 1170.
39. Melo, M., Barradas, P., Costa, A., Cristovao, M., Alves, P. Results of a randomized phase III trial comparing 4 cisplatin (P)-based regimens in the treatment of locally advanced and metastatic non-small cell lung cancer (NSCLC): Mitomycin/vinblastine/cisplatin (MVP) is no longer a therapeutic option. Proc Am Soc Clin Oncol, 2002, 21: 302a. Abstr. 1205.
40. Kodani, T., Ueoka, H., Kiura, K. et al. A phase III randomized trial comparing vindesine and cisplatin with or without ifosfamide in patients with advanced non-small-cell lung cancer: Long-term follow-up results and analysis of prognostic factors. Lung Cancer 2002, 36: 313-9.
41. Gebbia, V., Galetta, D., Riccardi, F. et al. Vinorelbine plus cisplatin versus cisplatin plus vindesine and mitomycin C in stage IIIB-IV non-small cell lung carcinoma: A prospective randomized study. Lung Cancer 2002, 37: 179-87.
42. Crino, L., Scagliotti, G., Ricci, S. et al. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol 1999, 17: 3522-30.
43. Comella, P. Phase III trial of cisplatin/gemcitabine with or without vinorelbine or paclitaxel in advanced non-small cell lung cancer. Sem Oncol 2001, 28 (2 Suppl. 7): 7-10.
44. Comella, P., Frasci, G., Panza, N. et al. Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer: Interim analysis of a phase III trial of the Southern Italy Cooperative Oncology Group. J Clin Oncol 2000, 18: 1451-7.
45. Alberola, V., Camps, C., Provencio, M. et al. Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: A Spanish Lung Cancer Group phase III randomized trial. J Clin Oncol 2003, 21: 3207-13.
46. Williamson, S., Crowley, J., Lara, P. et al. S0003: Paclitaxel/ carboplatin (PC) v PC + tirapazamine (PCT) in advanced non-small cell lung cancer (NSCLC). A Southwest Oncology Group (SWOG) trial. Proc Am Soc Clin Oncol 2003, 22: 622. Abstr. 2502.
47. Danson, S., Middleton, M.R., O'Byrne, K.J. et al. Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma. Cancer 2003, 98: 542-53.
48. Delbaldo, C., Syz, N., Michiels, S., Le Chevalier, T., Pignon, J.P. Adding a second or a third drug to a chemotherapy regimen in patients with advanced non-small-cell lung carcinoma (NSCLC): A meta-analysis of the literature. Proc Am Soc Clin Oncol 2003, 22: 623. Abstr. 2507.
49. Baggstrom, M.Q., Socinski, M.A., Hensing, T.A., Poole, C. Addressing the optimal number of cytotoxic agents in stage IIIB/IV non-small cell lung cancer (NSCLC): A meta-analysis of the published literature. Proc Am Soc Clin Oncol 2003, 22: 624. Abstr. 2501.
50. Georgoulias, V., Papadakis, E., Alexopoulos, A. et al. Cancer GOCGfL: Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: A randomised multicentre trial. Lancet 2001, 357: 1478-84.
51. Gridelli, C., Gallo, C., Shepherd, F.A. et al. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: A phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003, 21: 3025-34.
52. Kosmidis, P., Mylonakis, N., Nicolaides, C. et al. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: A phase III randomized trial. J Clin Oncol 2002, 20: 3578-85.
53. Kakolyris, S., Tsiafaki, X., Agelidou, A. Preliminary results of a multicenter randomzied phase III trial of docetaxel plus gemcitabine (DG) versus vinorelbine plus cisplatin (VC) in patients with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 2002, 21: 296a. Abstr. 1182.
54. Patel, R., Keiser, L., Justice, G. et al. ACORN 9901: A multicenter randomized trial of docetaxel plus gemcitabine versus weekly paclitaxel plus gemcitabine in patients (pts) with non-small-cell lung cancer. Proc Am Soc Clin Oncol 2002, 21: 320a. Abstr. 1276.
55. Wachters, F., Van Putten, J, Kramer, H. et al. Randomized multicenter phase III trial comparing gemcitabine in combination with cisplatin or epirubicine as first-line treatment in advanced non-small-cell lung cancer. Proc Am Soc Clin Oncol 2002, 21: 296a. Abstr. 1181.
56. Van Meerbeeck, J., Smit, E., Lianes, P. et al. A EORTC randomized phase III trial of three chemotherapy regimens in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2001, 20: 308a. Abstr. 1228.
57. Socinski, M., Schell, M., Peterman, A. et al. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol 2002, 20: 1335-43.
58. Smith, I., O'Brien, M., Talbot, D. et al. Duration of chemotherapy in advanced non-small-cell lung cancer: A randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol 2001, 19: 1336-43.
59. Depierre, A., Quoix, E., Mercier, M. Maintenance chemotherapy in advanced non-small cell lung cancer (NSCLC): A randomized study of vinorelbine (V) versus observation (OB) in patients (Pts) responding to induction therapy (French Cooperative Oncology Group). Proc Am Soc Clin Oncol 2001, 20: 309a. Abstr. 1231.
60. Hutchins, L.F., Unger, J.M., Crowley, J.J., Coltman, C.A., Jr., Albain, K.S. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999, 341: 2061-7.
61. Montella, M., Gridelli, C., Crispo, A. et al. Has lung cancer in the elderly different characteristics at presentation? Oncol Rep 2002, 9: 1093-6.
62. Yellen, S.B., Cella, D.F., Leslie, WT. Age and clinical decision making in oncology patients. J Natl Cancer Inst 1994, 86: 1766-70.
63. Langer, CJ., Vangel, M.G., Schiller, J. et al. Age-specific subanalysis of ECOG 1594: Fit elderly patients (70-80 YRS) with NSCLC do as well as younger pts (<70). Proc Am Soc Clin Oncol 2003, 22: 639. Abstr. 2571.
64. Kelly, K., Giarritta, S., Hayes, S. et al. Should older patients (pts) receive combination chemotherapy for advanced stage non-small cell lung cancer (NSCLC)? An analysis of Southwest Oncology Trials 9509 and 9308. Proc Am Soc Clin Oncol 2001, 20: 329a. Abstr. 1313.
65. Fossella, F.V., Belani, C.P. Phase III study (TAX 326) of docetaxel-cisplatin (DC) and docetaxel-carboplatin (DCb) versus vinorelbine-cisplatin (VC) for the first-line treatment of advanced/ metastatic non-small-cell lung cancer (NSCLC): Analyses in elderly patients. Proc Am Soc Clin Oncol 2003, 22: 629. Abstr. 2528.
66. Rocha Lima, C.M., Herndon, J.E., II, Kosty, M., Clamon, G., Green, M.R. Therapy choices among older patients with lung carcinoma: An evaluation of two trials of the Cancer and Leukemia Group B. Cancer 2002, 94: 181-7.
67. Gridelli, C., Perrone, F., Gallo, C. et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 2003, 95: 362-72.
68. Frasci, G., Lorusso, V., Panza, N. et al. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol 2000, 18: 2529-36.
69. Albain, K., Crowley, J., LeBlanc, M., Livingston, R. Survival determinants in extensive-stage non-small-cell lung cancer: The Southwest Oncology Group experience. J Clin Oncol 1991, 9: 1618-26.
70. Eton, D.T., Fairclough, D.L., Cella, D., Yount, S.E., Bonomi, P., Johnson, D.H. Early change in patient-reported health during lung cancer chemotherapy predicts clinical outcomes beyond those predicted by baseline report: Results from Eastern Cooperative Oncology Group Study 5592. J Clin Oncol 2003, 21: 1536-43.
71. Sweeney, J., Zhu, J., Sandler, A. et al. Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group E1594. Cancer 2001, 92: 2639-47.
72. Fossella, F., Devore, R., Kerr, R.N. et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with plantinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clinical Oncology 2000, 18:2354-62.
73. Shepherd, F., Dancey, J., Ramlau, R. et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Onc 2000, 18:2095-2103.
74. Leighl, N., Shepherd, R., Burkes, R., Goodwin, P. Economic analysis of the TAX 317 trial: Docetaxel versus best supportive care as second-line therapy of advanced non-small-cell lung cancer. J Clin Oncol 2002, 20: 1344-52.
75. Hanna, N.H., Shepherd, F.A., Rosell, R. et al. A phase III study of pemetrexed vs docetaxel in patients with recurrent non-small cell lung cancer (NSCLC) who were previously treated with chemotherapy. Proc Am Soc Clin Oncol 2003, 22: 622.
76. Gridelli, C., Illiano, A., Salvagni, S. et al. Effect on quality-of-life (QOL) of weekly vs. 3-weekly docetaxel (D) in second-line treatment of advanced non-small-cell lung cancer. The DISTAL randomized phase 3 trial. Proc Am Soc Clin Oncol 2003, 22: 625. Abstr. 2515.
77. Camps, C., Massuti, B., Jiménez, A.M. et al. Second-line docetaxel administered every 3 weeks versus weekly in advanced non-small-cell lung cancer (NSCLC): A Spanish Lung Cancer Group (SLCG) phase III trial. In: Grunberg, S.M. (Ed.). Proc Am Soc Clin Oncol 2003, 22: 625. Abstr. 2514.
78. Socinski, M.A., Schell, M.J., Bakri, K. et al. Second-line, low-dose, weekly paclitaxel in patients with stage IIIB/IV nonsmall cell lung carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxel. Cancer 2002, 95: 1265-73.
79. Crino, L., Mosconi, A.M., Scagliotti, G.V. et al. Gemcitabine as second-line treatment for relapsing or refractory advanced non-small cell lung cancer: A phase II trial. Semin Oncol 1998, 25 (4 Suppl. 9): 23-6.
80. Kris, M., Natale, R., Herbst, R. A phase II trial of ZD1839 ("Iressa') in advanced non-small cell lung cancer patients who had failed platinum-and docetaxel-based regimens. Proc Am Soc Clin Oncol 2002, 21: 292a. Abstr. 1166.
81. Fukuoka, M., Yano, S., Giaccone, G. et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003, 21: 2237-46.
82. Giaccone, G., Johnson, D., Manegold, C. et al. A phase III clinical trial of ZD1839 ('Iressa') in combination with gemcitabine and cisplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer (INTACT 1). Ann Oncol 2002, 13 (Suppl. 5): 2.
83. Johnson, D., Herbst, R., Giaconne, G. et al. ZD1839 ("Iressa") in combination with paclitaxel and carboplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer: Results from a phase III clinical trial (INTACT2). Ann Oncol 2002, 13 (Suppl. 5): 127-8.
84. Sirotnak, R, Zakowiski, M., Miller, V., Scher, H., Kris, M. Efficacy of cytotoxic agents against human tumorxenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 2000, 6: 4885-92.
85. Natale, R., Shak, S., Aronson, N. et al. Quantitative gene expression in non-small cell lung cancer from paraffin-embedded tissue specimens: Predicting response to gefitinib, an EGFR kinase inhibitor. Proc Am Soc Clin Oncol 2003, 22: 190. Abstr. 763.
86. Pérez-Soler, R., Chachoua, A., Huberman, M. et al. A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inihibitor, OSI-774, following platinum-based chemotherapy, in patients (pts) with advanced, EGFR-expressing, non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2001, 20: 310a. Abstr. 1235.
87. Kim, E., Mauer, A., Fossella, F. A phase II study of Erbitux (IMC-C225), an eidermal growth factor receptor blocking antibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small cell lung cancer. Proc Am Soc Clin One 2002, 21: 293a. Abstr. 1168.
88. Figlin, R., Belldegrun, A., Lohner, M. et al. ABX-EGF: A fully human anti-EGF receptor antibody in patients with advanced cancer. Proc Am Soc Clin Oncol 2001, 20: 276a. Abstr. 35.
89. Kollmannsberger, C., Schittenhelm, M., Honecker, F. et al. Epidermal growth factor receptor (EGFR) antibody EMD 72000 in combination with paclitaxel (P) in patients (pts) with EGFR-positive advanced non-small cell lung cancer (NSCLC): A phase I study. Proc Am Soc Clin Oncol 2003, 22: 627. Abstr. 2520.
90. Johnson, D., DeVore, R., Kabbinavar, F., Herbst, R., Holmgren, E., Novotny, W. Carboplatin (C) + paclitaxel (T) + RhuMab-VEGF (AVF) may prolong survival in advanced non-squamous lung cancer. Proc Am Soc Clin Oncol 2001, 20: 315a. Abstr. 1256.
91. Mininberg, E.D., Herbst, R.S., Henderson, T. et al. Phase I/II study of the recombinant humanized monoclonal anti-VEGF antibody bevacizumab and the EGFR-TK inhibitor erlotinib in patients with recurrent non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2003, 22: 627. Abstr. 2521.
92. Lynch, T.J., Raju, R., Lind, M. et al. Randomized phase III trial of chemotherapy and antisense oligonucleotide LY900003 (ISIS 3521) in patients with advanced NSCLC: Initial report. Proc Am Soc Clin Oncol 2003, 22: 623. Abstr. 2504.
93. Taketo, M.M. Cyclooxygenase-2 inhibitors in tumorigenesis (Part II). J Natl Cancer Inst 1998, 90: 1609-20.
94. Hida, T., Yatabe, Y, Achiwa, H. et al. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 1998, 58: 3761-4.
95. Csiki, I., Dang, T., Gonzalez, A. et al. Cyclooxygenase-2 (COX-2) inhibition + docetaxel (Txt) in recurrent non-small cell lung cancer (NSCLC): Preliminary results of a phase II trial (THO-0054). Proc Am Soc Clin Oncol 2002, 21: 297a. Abstr. 1187.
96. Carbone, D., Choy, H., Csiki, I. et al. Serum/ plasma VEGF level changes with cyclooxygenase-2 (COX-2) inhibition in combined modality therapy in stage III non-small cell lung cancer (NSCLC): Preliminary results of a phase II trial (THO-0059). Proc Am Soc Clin Oncol 2002, 21: 318a. Abstr. 1270.
97. Johnson, D.H., Csiki, I., Gonzalez, A. Cyclooxygenase-2 (COX-2) inhibition in non-small cell lung cancer (NSCLC): Preliminary results of a phase II trial. Proc Am Soc Clin Oncol 2003, 22: 640. Abstr. 2575.
98. Nemunaitis, J., Smith, J., Sterman, D. et al. A phase I/II trial of bystander GVAX cancer vaccine in non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2002, 21: 13a. Abstr. 48.
99. Adjei, A.A., Mauer, A., Marks, R. A phase II study of the farnesyltransferase inhibitor R115777 in patients with advanced non-small cell lung cancer. Proc Am Soc Clin Onc 2002, 21: 290a. Abstr. 1156.
100. Carbone, D., Adak, S., Schiller, J. Adenovirus p53 administered by bronchoalveolar lavage in patients with bronchioalveolar cell lung carcinoma (BAC). Proc Am Soc Clin Oncol 2003, 22: 620. Abstr. 2492.
101. Strumberg, D., Awada, A., Piccart, M. et al. Final report of the phase I clinical program of the novel raf kinase inhibitor BAY 43-9006 in patients with refractory solid tumors. Proc Am Soc Clin Oncol 2003, 22: 203. Abstr. 813.
102. Gordon, M.S., Mendelson, D., Guirguis, M.S., Knight, R.A., Humerickhouse, R.A. ABT-510, an anti-angiogenic, thrombospondin-1 (TSP-1) mimetic peptide, exhibits favorable safety profile and early signals of activity in a randomized phase IB trial. Proc Am Soc Clin Oncol 2003, 22: 195. Abstr. 780.
103. Stevenson, J., Nho, C.W., Schick, J. et al. Phase II clinical/ pharmacodynamic trial of the proteasome inhibitor PS-341 in advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 2003, 22: 202. Abstr. 810.
104. O'Brate, A., Taron, M., Gandara, D., Resell, R. Sharing new approaches to translational research in non-small cell lung cancer. Oncologist 2000, 5: 514-9.
105. Baggstrom, M.Q., Socinski, M.A., Hensing, T.A., Poole, C. Third generation chemotherapy regimens (3GR) improve survival over second generation regimens (2GR) in stage II-IB/IV non-small cell lung cancer (NSCLC): A meta-analysis of the published literature. Proc Am Soc Clin Oncol 2002, 21: 306a. Abstr. 1222.
106. Breathnach, O.S., Freidlin, B., Conley, B. et al. Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: Sobering results. J Clin Oncol 2001, 19: 1734-42.
107. Rosell, R., Taron, M., Alberola, V., Massuti, B., Felip, E. Genetic testing for chemotherapy in non-small cell lung cancer. Lung Cancer 2003, 41 (Suppl. 1): S97-102.